To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed
Primary Purpose
Ischemic Hepatitis
Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Standard Care + NAC (N -ACETYLCYSTEINE)
Standard Care (in control arm)
Sponsored by
About this trial
This is an interventional treatment trial for Ischemic Hepatitis
Eligibility Criteria
Inclusion Criteria:
- Age > 18 and < 75
- Cirrhotics with UGIE (Upper Gastrointestinal Endoscopy ) within last 24 hours.
Exclusion Criteria:
- Non cirrhotic
- Hepatocellular carcinoma
- Advanced cardiopulmonary disease
- Pregnancy
- Extrahepatic malignancy
- Patient on anticoagulation therapy
Sites / Locations
- Institute of Liver & Biliary Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Standard Care + NAC (N-ACETYLCYSTEINE) infusion
Standard Care
Arm Description
Outcomes
Primary Outcome Measures
To study the efficacy of NAC (N -ACETYLCYSTEINE) in preventing ischemic hepatitis in cirrhotics with upper Gastrointestinal bleed.
Secondary Outcome Measures
To study effect of NAC (N -ACETYLCYSTEINE) infusion on 5 day survival post bleed.
To study incidence of complication like AKI (Acute Kidney Injury), HE(Hepatic Encepahlopathy) and SBP(Spontaneous Bacterial Peritonitis).
Full Information
NCT ID
NCT02015403
First Posted
December 13, 2013
Last Updated
September 11, 2019
Sponsor
Institute of Liver and Biliary Sciences, India
1. Study Identification
Unique Protocol Identification Number
NCT02015403
Brief Title
To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed
Official Title
TO COMPARE THE EFFICACY OF N -ACETYLCYSTEINE AND STANDARD THERAPY VERSUS STANDARD THERAPY IN THE PREVENTION OF ISCHEMIC HEPATITIS AND SURVIVAL POST UPPER GI BLEED
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
December 2013 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
May 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patient presenting with upper GI bleed in ILBS (Institute of Liver and Biliary Sciences) emergency admitted to ICU (Intensive Care Unit) or shifted from ward to ICU (Intensive Care Unit) in view of upper GI bleed randomized to two groups
GROUP A : 110 Patients will receive standard care + NAC infusion for 72 hours
GROUP B : 110 Patients will receive standard care only
NAC will be given at following rate :
Initial loading of 150 mg/kg/hr over 1 hour Followed by 12.5mg/kg/hr for 4 hrs Then continuous infusion of 6.25 mg/kg for the remaining 67 hrs
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemic Hepatitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard Care + NAC (N-ACETYLCYSTEINE) infusion
Arm Type
Experimental
Arm Title
Standard Care
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Standard Care + NAC (N -ACETYLCYSTEINE)
Intervention Type
Drug
Intervention Name(s)
Standard Care (in control arm)
Primary Outcome Measure Information:
Title
To study the efficacy of NAC (N -ACETYLCYSTEINE) in preventing ischemic hepatitis in cirrhotics with upper Gastrointestinal bleed.
Time Frame
Day 5
Secondary Outcome Measure Information:
Title
To study effect of NAC (N -ACETYLCYSTEINE) infusion on 5 day survival post bleed.
Time Frame
6 weeks
Title
To study incidence of complication like AKI (Acute Kidney Injury), HE(Hepatic Encepahlopathy) and SBP(Spontaneous Bacterial Peritonitis).
Time Frame
day 5
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 and < 75
Cirrhotics with UGIE (Upper Gastrointestinal Endoscopy ) within last 24 hours.
Exclusion Criteria:
Non cirrhotic
Hepatocellular carcinoma
Advanced cardiopulmonary disease
Pregnancy
Extrahepatic malignancy
Patient on anticoagulation therapy
Facility Information:
Facility Name
Institute of Liver & Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India
12. IPD Sharing Statement
Citations:
PubMed Identifier
32048131
Citation
Maiwall R, Kumar A, Bhadoria AS, Jindal A, Kumar G, Bhardwaj A, Maras JS, Sharma MK, Sharma BC, Sarin SK. Utility of N-acetylcysteine in ischemic hepatitis in cirrhotics with acute variceal bleed: a randomized controlled trial. Hepatol Int. 2020 Jul;14(4):577-586. doi: 10.1007/s12072-020-10013-5. Epub 2020 Feb 11.
Results Reference
derived
Learn more about this trial
To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed
We'll reach out to this number within 24 hrs